Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

V E Shaw; D J Naisbitt; E Costello; W Greenhalf; B K Park; J P Neoptolemos; G W Middleton

doi:10.1586/erv.10.92

Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

V E Shaw, D J Naisbitt, E Costello, W Greenhalf, B K Park, J P Neoptolemos, G W Middleton

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.

Original language	English
Pages (from-to)	1007-16
Number of pages	10
Journal	Expert Review of Vaccines
Volume	9
Issue number	9
DOIs	https://doi.org/10.1586/erv.10.92
Publication status	Published - Sept 2010

Keywords

Cancer Vaccines
Humans
Immunotherapy
Neoplasms
Peptide Fragments
Telomerase
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/erv.10.92

Cite this

@article{9655059a29ec47d58bf40250d00db7da,

title = "Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer",

abstract = "GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.",

keywords = "Cancer Vaccines, Humans, Immunotherapy, Neoplasms, Peptide Fragments, Telomerase, Vaccination",

author = "Shaw, {V E} and Naisbitt, {D J} and E Costello and W Greenhalf and Park, {B K} and Neoptolemos, {J P} and Middleton, {G W}",

year = "2010",

month = sep,

doi = "10.1586/erv.10.92",

language = "English",

volume = "9",

pages = "1007--16",

journal = "Expert Review of Vaccines",

issn = "1476-0584",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

AU - Shaw, V E

AU - Naisbitt, D J

AU - Costello, E

AU - Greenhalf, W

AU - Park, B K

AU - Neoptolemos, J P

AU - Middleton, G W

PY - 2010/9

Y1 - 2010/9

N2 - GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.

AB - GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.

KW - Cancer Vaccines

KW - Humans

KW - Immunotherapy

KW - Neoplasms

KW - Peptide Fragments

KW - Telomerase

KW - Vaccination

U2 - 10.1586/erv.10.92

DO - 10.1586/erv.10.92

M3 - Article

C2 - 20822343

SN - 1476-0584

VL - 9

SP - 1007

EP - 1016

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

IS - 9

ER -

Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this